Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.

Aug 22 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing

Feb 23 2016

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Jan 14 2016

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug

Jan 10 2017

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

PTC Gambles On Success With <em>Emflaza</em>; Says Price Revision Is Needed

Mar 16 2017

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Feb 10 2017

Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk

Jun 13 2017

Related Companies

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Sarepta Therapeutics, Inc.

Marathon Pharmaceuticals LLC

Additional Topics

United States Advisory Committees Rare Diseases Regulation Drug Review FDA Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.